公开(公告)号：US20200332011A1

公开(公告)日：2020-10-22

申请号：US16852508

申请日：2020-04-19

Applicant: ImmunoBrain Checkpoint, Inc. ,  Yeda Research and Development Co. Ltd.

Inventor： Ester Yoles ,  Berit Olsen Krogh ,  Allan Jensen ,  Jan Egebjerg ,  Carol David ,  Kuti Baruch ,  Michal Eisenbach-Schwartz

IPC: C07K16/28

Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.

公开(公告)号：US20200297796A1

公开(公告)日：2020-09-24

申请号：US16899647

申请日：2020-06-12

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Sharon ,  Maria Gabriella Fuzesi-Levi

IPC: A61K38/10 ,  C12N15/113

Abstract: A method of treating a condition associated with aberrant protein degradation is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of an agent, which reduces the amount of CSN Acidic Protein (CSNAP) which is incorporated into the COP9 signalosome complex (CSN) of the cell.

公开(公告)号：US10781456B2

公开(公告)日：2020-09-22

申请号：US15737558

申请日：2016-06-22

Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. ,  Yeda Research and Development Co. Ltd., at the Weizmann Institute of Science

Inventor： Arren Bar-Even ,  Tobias Erb ,  Steffen Lindner ,  Philippe Marliere ,  Dan S. Tawfik

IPC: C12N15/82

Abstract: The present invention relates to an organism, a tissue, a cell or an organelle expressing enzymes which allow the conversion of 2-phosphoglycolate (2-PG; also known as glycolate 2-phosphate,) into an intermediate compound of the Calvin-Benson-Bassham Cycle (CBBC) without releasing CO2. The organism, tissue, cell or organelle of the invention may be genetically engineered, transgenic and/or transplastomic so as to express at least one enzyme which is involved in this conversion. The present invention further relates to an organism, tissue, cell or organelle which comprises/expresses at least one enzyme which is involved in this conversion. The present invention further relates to a method for producing an organism, tissue, cell or organelle of the invention. The present invention further relates to a method of enzymatically converting 2-PG into an intermediate compound of the CBBC without releasing CO2. The present invention further relates to the use of an organism, tissue, cell or organelle of the invention for enzymatically converting 2-PG into an intermediate compound of the CBBC without releasing CO2.

公开(公告)号：US20200289582A1

公开(公告)日：2020-09-17

申请号：US16885331

申请日：2020-05-28

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Chava ROSEN ,  Elias SHEZEN ,  Irit MILMAN KRENTSIS

IPC: A61K35/42 ,  A61K45/06 ,  A61K31/015 ,  A61K35/12 ,  A61K35/28 ,  C12N5/071 ,  A61K9/00 ,  A61K31/255 ,  A61K31/675 ,  A61N5/10

Abstract: A method of conditioning a subject in need of transplantation of progenitor cells in suspension of a tissue of interest is disclosed. The method comprising: (a) administering to a subject a therapeutically effective amount of an agent capable of inducing damage to the tissue of interest, wherein the damage results in proliferation of resident stem cells in the tissue; and subsequently (b) subjecting the subject to an agent which ablates the resident stem cells in the tissue. A method of transplanting progenitor cells in suspension of a tissue of interest to a subject in need thereof is also disclosed.

公开(公告)号：US20200225223A1

公开(公告)日：2020-07-16

申请号：US16748001

申请日：2020-01-21

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Irun R. COHEN ,  Eytan DOMANY ,  Francisco Javier QUINTANA ,  Guy HED ,  Gad GETZ

IPC: G01N33/564 ,  G16B20/00 ,  G01N33/68

Abstract: Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.

公开(公告)号：US20200225222A1

公开(公告)日：2020-07-16

申请号：US16650894

申请日：2018-09-17

Applicant: IMMUNARRAY LTD. ,  YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Rachel SOREK ,  Keren JAKOBI-BROOK ,  Pennina SAFER ,  Irun R. COHEN

IPC: G01N33/564 ,  G16B20/20 ,  G16B25/30 ,  G16B40/20

Abstract: Assays, kits and methods useful in the field of systemic lupus erythematosus (SLE) diagnosis and management for determining and providing SLE treatment adjustment include methods for detecting SLE resolution and for adjusting treatment in a subject hitherto diagnosed as having SLE.

公开(公告)号：US20200150125A1

公开(公告)日：2020-05-14

申请号：US16487849

申请日：2018-03-12

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Ayelet EREZ

IPC: G01N33/574

Abstract: Methods of diagnosing cancer are provided. Accordingly there is provided a method of diagnosing cancer in a subject, the method comprising determining a level of urea and/or a pyrimidine synthesis metabolite in a biological sample of the subject, wherein a level of urea below a predetermined threshold; and/or a said level of pyrimidine synthesis metabolite above a predetermined threshold; is indicative of cancer. Also provided are methods of prognosing and treating cancer.

公开(公告)号：US20200110144A1

公开(公告)日：2020-04-09

申请号：US15749518

申请日：2018-02-01

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Lucio FRYDMAN ,  Zhiyong ZHANG ,  Shimon Michael LUSTIG

IPC: G01R33/561 ,  G01R33/54

Abstract: A method for MRI imaging of a subject includes spatially encoding spins in a slice of the subject in orthogonal first and second directions. The encoding includes applying a chirped radiofrequency (RF) pulse concurrently with application of a magnetic field gradient pulse along the first direction. After applying of the RF pulse, a second chirped RF pulse is applied concurrently with application of a second magnetic field gradient pulse, with polarity opposite that of the first gradient pulse. An encoding magnetic field gradient, constant from applying the first RF pulse until the end of applying the second RF pulse, is concurrently applied along the second direction. Following the encoding, a spin signal is measured concurrently with application of a constant readout magnetic field gradient.

公开(公告)号：US20200095282A1

公开(公告)日：2020-03-26

申请号：US16704010

申请日：2019-12-05

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Moshe OREN ,  Varda ROTTER ,  Perry TAL

IPC: C07K7/06 ,  C07K14/47 ,  C07K7/08 ,  C07K14/00 ,  A61K38/08 ,  A61K38/16

Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.

公开(公告)号：US10590467B2

公开(公告)日：2020-03-17

申请号：US15303741

申请日：2015-04-16

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Ido Amit ,  David Lara-Astiaso ,  Meital Gury

IPC: C12Q1/68 ,  C07H21/00 ,  C12Q1/6816 ,  G01N33/53

Abstract: A method of analyzing DNA which, in a cell, is bound to a DNA binding moiety, the method comprising: (a) obtaining at least two samples of complexes of DNA bound to a DNA binding moiety; (b) isolating the complexes on a solid support; (c) labeling the DNA of the complexes, wherein the labeling distinguishes between the complexes of the first of the at least two samples and the complexes of the second of the at least two samples; (d) pooling the at least two samples of complexes; and (e) isolating the complexes using an agent which specifically binds to the DNA binding moiety; and (f) analyzing the DNA of the complexes.